OA
ALDR

Omega Advisors’s Alder Biopharmaceuticals ALDR Stock Holding History

Omega Advisors’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-189,500
Closed -$2.41M – 109
2018
Q1 		$2.41M Buy
+189,500
New +$2.74M 0.09% 73

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Omega Advisors's ALDR Position: Q2 2018 in Review

Omega Advisors sold out of Alder Biopharmaceuticals (ALDR) in Q2 2018, closing a stake of 189,500 shares — an estimated $2.41M sold.

Omega Advisors first reported a position in ALDR in Q1 2018 and held it in 1 quarter. The position peaked at $2.41M in Q1 2018. 139 funds tracked by Wall St. Rank hold ALDR as of Q2 2018.

  • Omega Advisors reported no remaining Alder Biopharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Omega Advisors sold 189,500 Alder Biopharmaceuticals shares in Q2 2018, an estimated $2.41M.
  • Omega Advisors first reported a position in Alder Biopharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Omega Advisors's Alder Biopharmaceuticals position peaked at $2.41M in Q1 2018.
  • 139 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2018.

Based on Omega Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.